Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Information
Adamas Pharmaceuticals last issued its earnings results on November 7th, 2019. The specialty pharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.90) by $0.09. The company earned $13.93 million during the quarter, compared to analyst estimates of $14.36 million. Adamas Pharmaceuticals has generated ($4.87) earnings per share over the last year. Adamas Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 2nd, 2020 based off prior year's report dates.
Adamas Pharmaceuticals Earnings Estimates and Actuals by Quarter
The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.
Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Estimates
2019 EPS Consensus Estimate: ($4.22)
2020 EPS Consensus Estimate: ($2.77)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2019 | 3 | ($1.31) | ($1.07) | ($1.21) |
| Q2 2019 | 3 | ($1.22) | ($0.85) | ($1.03) |
| Q3 2019 | 3 | ($1.18) | ($0.87) | ($1.02) |
| Q4 2019 | 3 | ($1.02) | ($0.80) | ($0.95) |
| Q1 2020 | 2 | ($0.96) | ($0.75) | ($0.86) |
| Q2 2020 | 2 | ($0.83) | ($0.62) | ($0.73) |
| Q3 2020 | 2 | ($0.75) | ($0.50) | ($0.63) |
| Q4 2020 | 2 | ($0.71) | ($0.42) | ($0.57) |
| Q1 2021 | 1 | ($0.54) | ($0.54) | ($0.54) |
| Q2 2021 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q3 2021 | 1 | ($0.44) | ($0.44) | ($0.44) |
Adamas Pharmaceuticals (NASDAQ ADMS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | GAAP EPS | Revenue Estimate | Actual Revenue | Conference Call | Details |
|---|
3/2/2020
(Estimated) | | | | | | | | |
| 11/7/2019 | 9/30/2019 | ($0.90) | ($0.99) | ($0.99) | $14.36 million | $13.93 million | Transcript | |
| 8/8/2019 | Q2 2019 | ($0.98) | ($0.90) | ($0.90) | $12.62 million | $12.69 million | N/A | |
| 5/9/2019 | 3/31/2019 | ($1.13) | ($1.08) | ($1.08) | $12.78 million | $11.67 million | N/A | |
| 3/4/2019 | Q4 | ($1.36) | ($1.06) | ($1.06) | $13.30 million | $13.32 million | Transcript | |
| 11/1/2018 | 9/30/2018 | ($1.34) | ($1.22) | ($1.22) | $10.10 million | $10.61 million | Transcript | |
| 8/2/2018 | Q2 2018 | ($1.41) | ($1.2570) | ($1.26) | $4.84 million | $7.57 million | N/A | |
| 5/3/2018 | Q1 2018 | ($1.37) | ($1.35) | ($1.35) | $1.71 million | $2.55 million | N/A | |
| 2/22/2018 | Q4 2017 | ($1.18) | ($1.27) | ($1.27) | $0.84 million | $0.57 million | N/A | |
| 11/2/2017 | Q3 2017 | ($1.01) | ($1.04) | ($1.04) | $0.03 million | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.81) | ($0.93) | ($0.93) | $0.03 million | $0.02 million | Listen | |
| 5/9/2017 | Q1 2017 | ($0.72) | ($0.72) | ($0.72) | $0.11 million | | Listen | |
| 2/28/2017 | Q4 | ($0.80) | ($0.68) | ($0.68) | $0.17 million | $0.04 million | N/A | |
| 11/3/2016 | Q3 2016 | ($0.83) | ($0.66) | ($0.66) | $0.26 million | $0.14 million | N/A | |
| 8/4/2016 | Q2 2016 | ($0.71) | ($0.78) | ($0.78) | $0.18 million | $0.22 million | N/A | |
| 5/10/2016 | Q1 | ($0.76) | ($0.65) | ($0.65) | | $0.18 million | N/A | |
| 2/23/2016 | Q4 | ($0.81) | ($0.58) | ($0.58) | $0.10 million | $0.52 million | N/A | |
| 11/12/2015 | Q3 | ($0.79) | ($0.81) | ($0.81) | $0.10 million | $0.77 million | N/A | |
| 8/11/2015 | Q215 | ($0.67) | ($0.78) | ($0.78) | $0.10 million | $0.40 million | N/A | |
| 5/13/2015 | Q414 | ($0.74) | ($0.69) | ($0.69) | $0.10 million | $0.23 million | N/A | |
| 3/3/2015 | Q4 2014 | $0.64 | $0.50 | $0.50 | $30.18 million | $30.30 million | N/A | |
| 11/4/2014 | Q314 | ($0.44) | ($0.57) | ($0.57) | $0.18 million | $0.22 million | N/A | |
| 8/7/2014 | Q214 | $2.07 | $0.88 | $0.88 | $18.75 million | $25.15 million | N/A | |
| 5/13/2014 | Q114 | ($0.09) | ($0.67) | ($0.67) | $30.60 million | $0.18 million | Transcript | |
(Earnings results data provided by Zacks Investment Research)
